Ciglitazone, ligand of peroxisome proliferator-activated receptor-γ, inhibits vascular endothelial growth factor activity

European Surgery - Acta Chirurgica Austriaca

Volumn 34, Issue 2, 2002, Pages 127-130

  Jozkowicz, Alicja ^a,b   Dulak, J ^b   Nigisch, Anneliese ^a   Weigel, G ^a   Sporn, E ^c   Fiigl, A ^a,c   Huk, I ^a,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c Ludwig Boltzmann Arrhythmia Research Institute   (Austria)

Author keywords

Angiogenesis; Endothelial cells; PPAR; Thiazolidinedione; Vascular endothelial growth factor

Indexed keywords

CIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VASCULOTROPIN;

CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MORPHOGENESIS; SPHEROID CELL; SPROUTING; UMBILICAL VEIN;

EID: 0036997935     PISSN: 16821769     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, Law RE: PPARγ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 1999;33:798-806.
3. Iijima K, Yoshizumi M, Ako J, Eto M, Kim S, Hashimoto M, Sugimoto N, Liang YQ, Sudoh N, Tona N, Ouchi Y: Expression of peroxisome proliferatoractivated receptor γ in rat aortic smooth muscle cells. Biochem Biophys Res Commun 1998;247:353-356.
4. Inoue M, Itoh H, Tanaka T, Chun TH, Doi K, Fukunaga Y, Sawada N, Yamshita J, Masatsugu K, Saito T, Sakaguchi S, Sone M, Yamahara KI, Yurugi T, Nakao K: Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-γ Arterioscler Thromb Vasc Biol 2001;21:560-566.
5. Jiang C, Ting AT, Seed B: PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-86.
6. Jozkowicz A, Dulak J, Piatkowska E, Placha W, Dembinska-Kiec A: Ligands of peroxisome proliferator-activated receptor-γ increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Bioch Pol 2000;47:1147-1157.
7. 2 induces synthesis of interleukin-8 by endothelial cells in a PPARγ-independent manner. Prostaglandind Other Lipid Mediat 2001;66: 165-177.
8. 2 on VEGF synthesis depends on the induction of heme oxygenase-1. Antioxidant Redox Signal, in press.
9. Kihara S, Ouchi N, Funahashi T, Shinohara E, Tamura R, Yamashita S, Matzsuzawa Y: Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells. Atherosclerosis 1998;136: 163-168.
10. Korff T, Augustin HG: Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol 1998;143:1341-1352.
11. Korff T, Augustin HG: Tension forces in fibrillar extracellular matrices control directional capillary sprouting. J Cell Science 1999;112:3249-3258.
12. Law RE, Goetza S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA: Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000; 101:1311-1318.
13. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-1905.
14. Lehmann JM, Moore LB, Smith-Olivier TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-γ (PPARγ). J Biol Chem 1995;270,12953-12956.
15. Mangelsdorf DJ, Evans RM: The RXR heterodimers and orphan receptors. Cell 1995;83:841-850.
16. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J: Peroxisome proliferator-activated receptor-activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998;83:1097-1103.
17. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J: Macrophages in human atheroma contain PPARγ differentiation-dependent peroxisomal proliferator-activated receptor-γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153:1723.
18. Michalik L, Wahli W: Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Current Opinion in Biotechnology 1999;10: 564-570.
19. 2 induces G1 arrest and differentiation marker expression in vascular smooth muscle cells. Mol Pharmacol 2000;58:837-844.
20. Momoi A, Murao K, Imachi H, Yoshitaka S, Nakamura H, Hosokawa H, Sato M, Fujita J, Okada H, Ishida T, Takahara J: Thiazolidinedione inhibits production of RANTES in cytokine-treated human lung epithelial cell line. FEBS Lett 1999;452:301-304.
21. Murao K, Imachi H, Atsuko M, Sayo Y, Hosokawa H, Sato M, Ishida T, Takahara J: Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett 1999; 454:27-30.
22. Murata T, He S, Hangai M, Ishibashi T, Xi XP, Kim S, Hsueh WA, Ryan S J, Law RE, Hinton DR: Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 2000;41:2309-2317.
23. Padilla J, Kaur K, Harris SG, Phipps RP: PPARγ-mediated regulation of normal and malignant B lineage cells. Ann NY Acad Sci 2000;905:97-109.
24. Palakhurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res 2001;61:6213-6218.
25. Ribon V, Johnson, JH, Camp HS, Saltiel AR: Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor gamma activation stimulates the expression of CAP gene. Proc Natl Acad Sci USA1998;95:14751-14756.
26. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
27. Risau W: Mechanism of angiogenesis. Nature 1997;386:671-674.
28. Schoonjans K, Steals B, Auwerx J: The peroxisome proliferator activated receptor (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochem Biocphys Acta 1996;1302:93-109.
29. Takashima T, Fujiwara Y, Higuchi K, Arakawa T, Yano Y, Hasuma T, Otani S: PPAR-γ ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of omithine decarboxylase activity. Int J Oncol 2001; 19:465-471.
30. Vernon RB, Angello JC, Iruela-Arispe ML, Lane TF, Sage EH: Reorganization of basement membrane matrices by cellular traction promotes the formation of cellular networks in vitro. Lab Invest 1992;66:536-547.
31. Wakino S, Kintscher U, Kim U, Yin F, Hsueh WA, Law RE: Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and G1 to S transition in vascular smooth muscle cells. J Biol Chem 2000;275: 22 435-22 441.
32. Xin X, Yang S, Kowalski J, Gerritsen ME: Peroxisome proliferator-activated receptor-γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-9121.
33. Yamakawa K, Hosoi M, Koyama H, Tanaka S, Fukumoto S, Morii H, Nishizawa Y: Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 2000;271:571-574.
34. Yoshimoto T, Naruse M, Shizume H, Naruse K, Tanabe A, Tanaka M, Tago K, Irie K, Muraki T, Demura H, Zardi L: Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 1999;145:333-340.